XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer

XBiotech’s vilamakitug shows strong survival benefit in right-sided colorectal cancer Phase II trial.

What the company is saying

XBiotech Inc. reports that the randomized Phase II portion of the TASKIN clinical trial met its pre-specified primary efficacy endpoint for vilamakitug (XB2001, Natrunix™) in refractory metastatic colorectal cancer. The company emphasizes that 61.3% of patients in the vilamakitug arm were alive at 12 months, exceeding the protocol threshold and outperforming the control arm’s 55.7%. The announcement highlights a pronounced and statistically significant survival benefit in the right-sided tumor subgroup, with a 62% reduction in risk of death and a 61% reduction in risk of treatment strategy failure, both supported by hazard ratios and p-values. XBiotech frames these results as providing a clear biological rationale for targeting IL-1α and as a validated direction for advancing vilamakitug toward registrational development. The tone is confident, with both the principal investigator, Professor François Ghiringhelli, and XBiotech’s interim CEO, Sushma Shivaswamy, stressing the clinical and biological significance of the findings. The company also points to high compliance (96.4%) and low discontinuation rates (1.3%) as evidence of feasibility and tolerability.

What the data suggests

The TASKIN Phase II trial enrolled 159 evaluable patients with refractory metastatic colorectal cancer, randomized 1:1 to vilamakitug or placebo plus standard chemotherapy. At 12 months, 61.3% (49/80) of patients in the vilamakitug arm were alive, compared to 55.7% (44/79) in the control arm, surpassing the efficacy threshold of 42 survivors. The 12-month time to strategy failure rate was 31.2% for vilamakitug versus 20.3% for control, and median progression-free survival was 5.9 months versus 5.6 months, with 12-month PFS rates of 25.0% and 21.0%, respectively. In the right-sided tumor subgroup (n=37), vilamakitug achieved a hazard ratio of 0.38 for overall survival (95% CI: 0.14–0.99; Cox p=0.047, log-rank p=0.038) and 0.39 for time to strategy failure (95% CI: 0.18–0.85; Cox p=0.017, log-rank p=0.014), indicating statistically significant and clinically meaningful benefit. Treatment adherence was high, with a 96.4% compliance rate for trifluridine/tipiracil and only a 1.3% permanent discontinuation rate for vilamakitug/placebo. The data are robust for a Phase II study, especially in the right-sided subgroup, but broader survival and PFS differences are more modest and not statistically significant in the overall population. No financial metrics or operational costs are disclosed.

Analysis

The announcement provides detailed, realised clinical efficacy and safety data from a completed Phase II trial, including survival rates, progression-free survival, and statistically significant subgroup results. The only forward-looking claim is the intent to advance vilamakitug toward registrational development, which is proportionate to the evidence presented. There is no exaggerated language or overstatement of future benefits; the tone is positive but grounded in disclosed results. No large capital outlay or immediate financial impact is discussed, and the study was externally funded. The gap between narrative and evidence is minimal, with most claims substantiated by numerical data. The absence of financial metrics is not a deficiency for a biotech at this stage.

Risk flags

• ●The transition from Phase II to registrational trials introduces substantial execution risk, as larger, multi-center Phase III studies require significant funding, operational capacity, and regulatory engagement that XBiotech has not yet secured or disclosed.
• ●The statistically significant benefit is concentrated in the right-sided tumor subgroup (n=37), a relatively small sample, raising the risk that broader efficacy may not be replicated in larger or more diverse populations.
• ●No financial data, funding commitments, or partnership arrangements for future trials are disclosed, leaving uncertainty about XBiotech’s ability to finance and execute the next development stages.
• ●The study was externally funded by the French National Cancer Institute, so XBiotech’s internal capital exposure to future trials is unknown and could be material if external support is not renewed.
• ●The overall survival and progression-free survival benefits in the full study population are modest and not statistically significant, which could limit regulatory or commercial enthusiasm outside the right-sided subgroup.

Bottom line

XBiotech’s Phase II TASKIN trial results show that vilamakitug delivers a statistically significant and clinically meaningful survival benefit for patients with right-sided metastatic colorectal cancer, a subgroup with high unmet need. The overall population saw more modest improvements, and only the right-sided subgroup reached statistical significance for survival and strategy failure endpoints. High treatment compliance and low discontinuation rates support the drug’s feasibility in combination regimens. However, the company has not disclosed plans, funding, or timelines for a registrational (Phase III) trial, and the next steps toward commercialization remain undefined. The lack of financial data and reliance on external funding add uncertainty about XBiotech’s ability to capitalize on these results. For investors, the most important takeaway is that vilamakitug has strong potential in a defined patient subset, but substantial clinical, operational, and financial hurdles remain before any commercial value can be realized.

Announcement summary

(NASDAQ:XBIT) XBiotech Inc. announced positive final efficacy results from the randomized Phase II portion of the multicenter TASKIN clinical trial evaluating vilamakitug (XB2001, Natrunix™) in refractory metastatic colorectal cancer (mCRC). The TASKIN study was investigator-sponsored, funded by the French National Cancer Institute (INCa), and coordinated by Centre Georges-François Leclerc (CGFL) in Dijon, France. The Phase II study met its pre-specified primary efficacy success criterion under a Simon two-stage design. At the 12-month landmark analysis, 49 of 80 evaluable patients (61.3%) in the vilamakitug arm were alive, exceeding the protocol-defined threshold of 42 or more survivors. In the control arm, 44 of 79 evaluable patients (55.7%) were alive at 12 months. The 12-month Time to Strategy Failure (TSF) rate was 31.2% in the vilamakitug arm versus 20.3% in the control arm (log-rank p = 0.17). Median Progression-Free Survival (PFS) was 5.9 months for vilamakitug versus 5.6 months for control, with a 12-month PFS rate of 25.0% versus 21.0% (log-rank p = 0.42). Vilamakitug demonstrated a 96.4% mean compliance rate for trifluridine/tipiracil and only a 1.3% permanent discontinuation rate for vilamakitug/placebo. An exploratory analysis in patients with right-sided (proximal) primary tumors (n = 37) showed a statistically significant 62% reduction in risk of death for vilamakitug compared to control (HR = 0.38; 95% CI: 0.14–0.99; Cox p = 0.047, log-rank p = 0.038) through 12 months. In the same subgroup, vilamakitug achieved a 61% reduction in risk of treatment strategy failure compared to control (HR = 0.39; 95% CI: 0.18–0.85; Cox p = 0.017, log-rank p = 0.014) through 12 months. Professor François Ghiringhelli, M.D., Ph.D., Principal Investigator and Director of Oncology at CGFL, highlighted the pronounced clinical survival advantage in right-sided colorectal cancers and the biological rationale for targeting IL-1α. Sushma Shivaswamy, Ph.D., Chief Scientific Officer and Interim Chief Executive Officer of XBiotech, stated that the TASKIN trial provides a validated direction for advancing vilamakitug toward registrational clinical development. The TASKIN study (NCT05201352) was conducted across clinical cancer centers in France, with the Phase I portion determining safety and recommended Phase II dose, and the double-blind Phase II portion enrolling heavily pre-treated refractory mCRC patients randomized 1:1 to receive standard-of-care trifluridine/tipiracil (± bevacizumab) with either vilamakitug or placebo. Vilamakitug is a True Human™ monoclonal antibody developed solely by XBiotech, derived from a human donor with a natural immune response against IL-1α, and has been shown clinically to reduce levels of VEGF-A, ErbB2/HER2, PDGF, and EGF in cancer patients.

Disagree with this article?